Literature DB >> 27631180

Evaluation of miR-182/miR-100 Ratio for Diagnosis and Survival Prediction in Bladder Cancer.

Zhanguo Chen1, Lili Wu2, Qi Lin3, Jing Shi4, Xiangyang Lin1, Liang Shi1.   

Abstract

BACKGROUND: Abnormal expression of microRNAs (miRNAs) plays an important role in development of several cancer types, including bladder cancer (BCa). However, the relationship between the ratio of miR-181/miR-100 and the prognosis of BCa has not been studied yet. The aim of this study was to evaluate the expression of miR-182, miR-100 and their clinical significance in BCa.
METHODS: Upregulation of miR-182 and down-regulation of miR-100 were validated in tissue specimens of 134 BCa cases compared with 148 normal bladder epithelia (NBE) specimens  using TaqMan-based real-time reverse transcription quantitative PCR (RT-qPCR). The diagnostic and prognostic evaluation of miR-182, miR-100, and miR-182/miR-100 ratio was also performed.
RESULTS: miR-182 was upregulated in BCa and miR-100 was down-regulated in BCa compared with NBE (P < 0.001). The areas under receiver operating characteristic curves (AUCs-ROC) for miR-182 and miR-100 were 0.913 and 0.810, respectively. However, miR-182/miR-100 ratio increased the diagnostic performance, yielding an AUC of 0.981 (97.01% sensitivity and 90.54% specificity). Moreover, miR-182/miR-100 ratio was associated with pT-stage, histological grade, BCa recurrence and carcinoma in situ (P < 0.05 for all). Multivariate Cox regression analysis indicated that miR-182/miR-100 ratio was an independent prognostic factor for overall survival (Hazard ratio: 7.142; 95% CI: 2.106 - 9.891; P < 0.01). Furthermore, Kaplan-Meier curve analysis revealed that high-level of miR-182/miR-100 ratio was significantly correlated with shortened survival time for BCa patients (P < 0.01).
CONCLUSION: The miR-182/miR-100 ratio may serve as a novel promising biomarker for diagnosis and survival prediction in BCa. Further studies are needed to elucidate the role of miR-182/miR-100 ratio as a non‑invasive diagnostic tool for BCa.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27631180     DOI: 0161909/AIM.008

Source DB:  PubMed          Journal:  Arch Iran Med        ISSN: 1029-2977            Impact factor:   1.354


  7 in total

1.  The Upregulation of hsa-mir-181b-1 and Downregulation of Its Target CYLD in the Late-Stage of Tumor Progression of Breast Cancer.

Authors:  Alireza Andalib; Shadi Rashed; Moein Dehbashi; Jamshid Hajati; Farshid Noorbakhsh; Mazdak Ganjalikhani-Hakemi
Journal:  Indian J Clin Biochem       Date:  2019-03-21

2.  MiR-218 and miR-100 polymorphisms as markers of irinotecan-based chemotherapy response in metastatic colorectal cancer.

Authors:  Dimitra-Ioanna Lampropoulou; Gerasimos Aravantinos; Konstantinos Laschos; Theodosis Theodosopoulos; Christos Papadimitriou; Maria Gazouli
Journal:  Int J Colorectal Dis       Date:  2019-10-09       Impact factor: 2.571

3.  circRNA CRIM1 regulates the migration and invasion of bladder cancer by targeting miR182/Foxo3a axis.

Authors:  X Y Yu; C Q Ma; Y H Sheng
Journal:  Clin Transl Oncol       Date:  2022-01-07       Impact factor: 3.405

4.  MiR-181a, a new regulator of TGF-β signaling, can promote cell migration and proliferation in gastric cancer.

Authors:  Shaohua Ge; Haiyang Zhang; Ting Deng; Wu Sun; Tao Ning; Qian Fan; Yi Wang; Xinyi Wang; Qiumo Zhang; Zhengyang Zhou; Haiou Yang; Guoguang Ying; Yi Ba
Journal:  Invest New Drugs       Date:  2019-01-04       Impact factor: 3.850

5.  Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer.

Authors:  Jinhua Zhang; Gottumakkala S Raju; David W Chang; Shu-Hong Lin; Zhinan Chen; Xifeng Wu
Journal:  Cancer       Date:  2017-11-07       Impact factor: 6.860

Review 6.  Role of Non-Coding RNAs in the Etiology of Bladder Cancer.

Authors:  Caterina Gulìa; Stefano Baldassarra; Fabrizio Signore; Giuliano Rigon; Valerio Pizzuti; Marco Gaffi; Vito Briganti; Alessandro Porrello; Roberto Piergentili
Journal:  Genes (Basel)       Date:  2017-11-22       Impact factor: 4.096

7.  Identifying a panel of genes/proteins/miRNAs modulated by arsenicals in bladder, prostate, kidney cancers.

Authors:  Andrea Polo; Silvia Marchese; Giuseppina De Petro; Maurizio Montella; Gennaro Ciliberto; Alfredo Budillon; Susan Costantini
Journal:  Sci Rep       Date:  2018-07-10       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.